News
PDPHF
0.829
NaN%
--
Egetis Therapeutics Sets Nomination Committee for 2027 AGM
TipRanks · 5d ago
Egetis bolsters tiratricol case with largest RTH-beta cohort study
TipRanks · 10/16 13:57
Egetis Therapeutics Adjusts Share Composition After Employee Stock Option Exercise
TipRanks · 09/30 16:34
Cantor Fitzgerald Reaffirms Their Buy Rating on Egetis Therapeutics AB (P0F)
TipRanks · 09/29 13:05
Egetis Wins First U.S. FDA Approval for MCT8 Deficiency Therapy EMCITATE
TipRanks · 09/28 22:02
Egetis to Present New Emcitate Data at Major European Endocrinology Meetings
TipRanks · 09/04 06:33
Egetis Steps Up Investor Outreach Ahead of Key FDA Decision
TipRanks · 09/03 06:32
Egetis Wins Japanese Orphan Status for Emcitate in Rare MCT8 Disorder
TipRanks · 08/31 06:34
Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
TipRanks · 08/21 05:33
Egetis sets Q2 2026 results date as Emcitate nears key FDA decision
TipRanks · 08/07 12:41
Egetis Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 06/25 12:06
Egetis Therapeutics AB (P0F) Gets a Buy from Cantor Fitzgerald
TipRanks · 06/25 11:56
More
Webull provides a variety of real-time PDPHF stock news. You can receive the latest news about EGETIS THERAPEUTICS AB through multiple platforms. This information may help you make smarter investment decisions.
About PDPHF
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.